On 6 June 2017, the World Health Organization (WHO) published updates to its ‘Essential Medicines List’ (EML). Read more here.

Extended deadline (from 1 July to 31 July) 2017 for call to submit papers on effectiveness and cost-effectiveness of screening and prevention of infectious diseases among newly arrived migrants in Europe. Read more here.

Eurosurveillance is on the updated list of the Directory of Open Access Journals and in the SHERPA/RoMEO database. Read more here.

Follow Eurosurveillance on Twitter: @Eurosurveillanc

In this issue

Home Eurosurveillance Edition  2016: Volume 21/ Issue 41 Article 4
Back to Table of Contents
Previous Download (pdf)

Eurosurveillance, Volume 21, Issue 41, 13 October 2016
Bruggink, Catton, and Marshall: Authors’ reply: A norovirus intervariant GII.4 recombinant in Victoria, Australia, June 2016: the next epidemic variant? Reflections and a note of caution

+ Author affiliations

Citation style for this article: Bruggink L, Catton M, Marshall J. Authors’ reply: A norovirus intervariant GII.4 recombinant in Victoria, Australia, June 2016: the next epidemic variant? Reflections and a note of caution. Euro Surveill. 2016;21(41):pii=30373. DOI:

Received:04 October 2016; Accepted:06 October 2016

To the editor: We thank the authors of the letter to the editor for their interest in our report of the detection of a potential new epidemic strain of norovirus [1]. The authors express some doubt as to the validity of our claims of a possible new norovirus GII.4 variant, since the recombinant form (GII.4_NewOrleans_2009/GII.4_Sydney_2012) has been reported previously in a number of instances, including by their own laboratory [2]. Nevertheless we stand by our proposal that a potential new epidemic strain of GII.4 norovirus has arisen, for the reasons outlined below.

Firstly, we proposed that the new epidemic variant is not the recombinant itself, but a derivative of it that has altered enough, we think, to evade herd immunity. The recombinant was not claimed to be in itself ‘new’, but only the precursor of the altered version with epidemic potential. The ORF1-ORF2 sequence submitted to GenBank, as cited in our publication [1], was of the first detection of the recombinant in Victoria, Australia, and was not the proposed new variant. That sequence was used to properly establish the existence of the recombinant, as the sequence bridges both ORF1 and ORF2 in one fragment. A full capsid sequence of the altered form of the recombinant was lodged in GenBank (KX767083) and, as cited in our publication [1], is 96.3% similar to its closest counterpart Sydney_2012, which is within the range of nucleotide difference presented by previous established epidemic variants, as calculated in our publication [1].

Regarding only referencing work at the Centers for Disease Prevention and Control (CDC) in the United States [3] for previous detection of the recombinant form, the reference was used purely because the data refer to an altered version of Sydney_2012, the ‘Sydney_2015’ strain. In fact, the data [3] do not actually refer to the recombinant (GII.4_NewOrleans_2009/GII.4_Sydney_2012), as the work only appears to be based on ORF2 data, as stated in our publication [1]. Other references to the recombinant form (GII.4_NewOrleans_2009/GII.4_Sydney_2012) were not cited, as the publication was primarily about the possible detection of an altered form of the recombinant, rather than the recombinant itself, and, importantly, highlighted the time delay between detection of a new variant and the resultant epidemic. We are not aware of any publication, other than the CDC data [3], that refers to an altered version of the recombinant or of GII.4_Sydney_2012 (ORF2) in general.

Finally, we agree that non-structural viral proteins may not have a direct role in a virus escaping herd immunity, but there is a sizeable literature on non-structural viral proteins playing important roles in viral virulence, of which the influenza non-structural protein 1 is but one well-characterised example [4].

Conflict of interest

None declared.

Authors’ contributions

Ms Bruggink prepared the response, Dr Catton and Dr Marshall assisted in the preparation.


  1. Bruggink L, Catton M, Marshall J. A norovirus intervariant GII.4 recombinant in Victoria, Australia, June 2016: the next epidemic variant?Euro Surveill. 2016;21(39):pii=30353.

  2. Fonager J, Barzinci S, Fischer TK. Emergence of a new recombinant Sydney 2012 norovirus variant in Denmark, 26 December 2012 to 22 March 2013.Euro Surveill. 2013;18(25):20506. DOI: 10.2807/1560-7917.ES2013.18.25.20506 PMID: 23806295

  3. Centers for Disease Control and Prevention (CDC). CaliciNet Data. Atlanta, GA: CDC. [Accessed 28 Sep 2016]. Available from:

  4. Barba M, Daly JM. The influenza NS1 protein: what do we know in equine influenza virus pathogenesis?Pathogens. 2016;5(3). pii: E57. DOI: 10.3390/pathogens5030057 PMID: 27589809

Back to Table of Contents
Previous Download (pdf)

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN] - ©2007-2016. All rights reserved

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.